Le Lézard
Classified in: Covid-19 virus

Global Breast Cancer Liquid Biopsy Markets, 2012-2019 & 2020-2027 - cfDNA, CTCs, EVs, Reference Laboratories, Hospitals & Physician Laboratories - ResearchAndMarkets.com


The "Breast Cancer Liquid Biopsy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Breast Cancer Liquid Biopsy Market to Reach $936.3 Million by 2027

Amid the COVID-19 crisis, the global market for Breast Cancer Liquid Biopsy estimated at US$262.6 Million in the year 2020, is projected to reach a revised size of US$936.3 Million by 2027, growing at a CAGR of 19.9% over the analysis period 2020-2027.

Cell-Free DNA (cfDNA), one of the segments analyzed in the report, is projected to record a 20.1% CAGR and reach US$387.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Circulating Tumor Cells (CTCs) segment is readjusted to a revised 22.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $78.3 Million, While China is Forecast to Grow at 19.5% CAGR

The Breast Cancer Liquid Biopsy market in the U.S. is estimated at US$78.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$164.4 Million by the year 2027 trailing a CAGR of 19.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.9% and 16.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.

Extracellular Vesicles (EVs) Segment to Record 17.5% CAGR

In the global Extracellular Vesicles (EVs) segment, USA, Canada, Japan, China and Europe will drive the 17.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$41.3 Million in the year 2020 will reach a projected size of US$127.2 Million by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$109.2 Million by the year 2027.

Select Competitors (Total 34 Featured):

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/csj79u


These press releases may also interest you

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Amplitude, Inc. . Shareholders who purchased shares of AMPL during...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ....

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...



News published on and distributed by: